| Who should measure quality of life, the doctor or the patient? ML Slevin, H Plant, D Lynch, J Drinkwater, WM Gregory British journal of cancer 57 (1), 109-112, 1988 | 1360 | 1988 |
| Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. ML Slevin, L Stubbs, HJ Plant, P Wilson, WM Gregory, PJ Armes, ... British Medical Journal 300 (6737), 1458-1460, 1990 | 1028 | 1990 |
| Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine‐6‐glucuronide R Osborne, S Joel, D Trew, M Slevin Clinical Pharmacology & Therapeutics 47 (1), 12-19, 1990 | 571 | 1990 |
| A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ML Slevin, PI Clark, SP Joel, S Malik, RJ Osborne, WM Gregory, DG Lowe, ... Journal of Clinical Oncology 7 (9), 1333-1340, 1989 | 528 | 1989 |
| Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment SM Downer, MM Cody, P McCluskey, PD Wilson, SJ Arnott, TA Lister, ... Bmj 309 (6947), 86-89, 1994 | 519 | 1994 |
| Morphine intoxication in renal failure: the role of morphine-6-glucuronide. RJ Osborne, SP Joel, ML Slevin Br Med J (Clin Res Ed) 292 (6535), 1548-1549, 1986 | 468 | 1986 |
| Analgesic activity of morphine-6-glucuronide R Osborne, S Joel, D Trew, M Slevin The Lancet 331 (8589), 828, 1988 | 330 | 1988 |
| The clinical pharmacology of etoposide and teniposide PI Clark, ML Slevin Clinical pharmacokinetics 12 (4), 223-252, 1987 | 320 | 1987 |
| Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. PW Thavasu, S Longhurst, SP Joel, ML Slevin, FR Balkwill Journal of immunological methods 153 (1-2), 115-124, 1992 | 315 | 1992 |
| The analgesic activity of morphine‐6‐glucuronide. R Osborne, P Thompson, S Joel, D Trew, N Patel, M Slevin British journal of clinical pharmacology 34 (2), 130-138, 1992 | 305 | 1992 |
| Multiple myeloma treated with high dose intravenous melphalan PJ Selby, TJ McElwain, AC Nandi, TJ Perren, RL Powles, CR Tillyer, ... British journal of haematology 66 (1), 55-62, 1987 | 291 | 1987 |
| Intensive treatment of multiple myeloma and criteria for complete remission ME Gore, C Viner, M Meldrum, J Bell, S Milan, A Zuiable, M Slevin, ... The Lancet 334 (8668), 879-882, 1989 | 257 | 1989 |
| The pharmacokinetics of morphine and morphine glucuronides in kidney failure R Osborne, S Joel, K Grebenik, D Trew, M Slevin Clinical Pharmacology & Therapeutics 54 (2), 158-167, 1993 | 242 | 1993 |
| Emotional support for cancer patients: what do patients really want? ML Slevin, SE Nichols, SM Downer, P Wilson, TA Lister, S Arnott, J Maher, ... British journal of cancer 74 (8), 1275-1279, 1996 | 240 | 1996 |
| Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer PD Peppercorn, RH Reznek, P Wilson, ML Slevin, RK Gupta British journal of cancer 77 (11), 2008-2011, 1998 | 206 | 1998 |
| The clinical pharmacology of etoposide ML Slevin Cancer 67 (S1), 319-329, 1991 | 173 | 1991 |
| Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. ML Slevin, EM Piall, GW Aherne, VJ Harvey, A Johnston, TA Lister Journal of Clinical Oncology 1 (9), 546-551, 1983 | 173 | 1983 |
| Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. M Gore, P Mainwaring, R A'hern, V MacFarlane, M Slevin, P Harper, ... Journal of clinical oncology 16 (7), 2426-2434, 1998 | 168 | 1998 |
| Volunteers or victims: patients' views of randomised cancer clinical trials M Slevin, J Mossman, A Bowling, R Leonard, W Steward, P Harper, ... British journal of cancer 71 (6), 1270-1274, 1995 | 152 | 1995 |
| Randomized placebo‐controlled trial of the activity of the morphine glucuronides RT Penson, SP Joel, K Bakhshi, SJ Clark, RM Langford, ML Slevin Clinical Pharmacology & Therapeutics 68 (6), 667-676, 2000 | 149 | 2000 |
